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Abstract
Background: Aspiration sclerotherapy is an effective therapeutic option for large symptomatic hepatic cysts.
However, incomplete cyst reduction following aspiration sclerotherapy is frequently reported. Strong post-procedural
cyst fluid secretion by cholangiocytes, which line the epithelium of the hepatic cyst, seems to be associated with lower
reduction rates. Previous studies showed that somatostatin analogues curtail hepatic cyst fluid production. This trial will
evaluate the effect of aspiration sclerotherapy combined with the somatostatin analogue pasireotide on cyst reduction.
By combining treatment modalities we aim to improve cyst reduction leading to greater symptomatic relief and
reduced rates of cyst recurrence.
Methods/Design: This single center, randomized, double-blind, placebo-controlled clinical trial evaluates the additional
effect of pasireotide when combined with aspiration sclerotherapy in patients with a large (>5 cm) symptomatic
hepatic cyst. A total of 34 participants will be randomized in a 1:1 ratio. In the active arm, patients will receive
pasireotide (long-acting release, 60 mg injection) two weeks prior to and two weeks following aspiration
sclerotherapy. Patients in the control arm will receive placebo injections at corresponding intervals. The primary
outcome is proportional cyst diameter reduction four weeks after aspiration sclerotherapy compared to baseline
measurements, obtained by ultrasonography. As secondary outcomes, proportional volume reduction, recurrence,
symptomatic relief and improvement of health-related quality of life will be assessed. Furthermore, safety and
tolerability of the combination of pasireotide and aspiration sclerotherapy will be evaluated.
Discussion: This trial aims to improve efficacy of aspiration sclerotherapy by a combined approach of two treatment
modalities. We hypothesize that pasireotide will decrease fluid re-accumulation after aspiration sclerotherapy, leading
to effective hepatic cyst reduction and symptomatic relief.
Trials registration: This trial is registered with ClinicalTrials.gov (identifier: NCT02048319; registered on 6 January 2014)
and EudraCT (identifier: 2013-003168-29; registered on 16 August 2013).
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Background
Hepatic cysts are fluid-filled cavities originating from
congenital malformations of biliary duct cells. Isolated
cysts occur at a prevalence of 2.5 to 18%, while polycystic
liver disease (PLD) is infrequent [1-4]. Large or multiple
hepatic cysts may cause symptomatic disease. Mass-
related symptoms include abdominal distension, pain,
postprandial fullness, nausea and dyspnea, collectively
leading to a compromised health-related quality of life
[5,6]. Treatment should be considered in all symptomatic
patients [4,7]. Aspiration sclerotherapy (AS) is a minimally
invasive procedure indicated for both solitary and domin-
ant hepatic cysts in PLD. AS includes percutaneous drain-
age of cyst fluid with subsequent intracystic instillation of
a sclerosing agent (such as ethanol or tetracycline) aiming
to destroy the inner cystic lining of cholangiocytes [8,9].
However, the efficacy of AS is limited due to direct fluid
re-accumulation following treatment [10]. Although re-
accumulation is transient, strong fluid secretion is associ-
ated with lower efficacy rates leading to failure of symptom
relief and the necessity to re-intervene [7,10,11].
Somatostatin analogues inhibit cyst fluid production
[12]. Several randomized clinical trials demonstrated
that somatostatin analogues (octreotide and lanreotide)
decrease polycystic liver volume [13-15]. Pasireotide
(SOM230) is a more potent somatostatin analogue com-
pared to conventional somatostatin analogues as it has a
broader binding profile and stronger affinity to its recep-
tors [16,17]. We hypothesize that pasireotide administra-
tion reduces fluid re-accumulation following AS and
therefore increases diameter reduction. We expect that
inhibited re-accumulation results in effective symptom-
atic relief and reduced recurrence rates. To this end, we
have designed a randomized, double-blind, placebo-
controlled clinical trial to evaluate clinical efficacy of AS
combined with pasireotide.
Methods/Design
Study aim
The primary objective of the SCLEROCYST trial is to
evaluate the combined effect of AS and pasireotide on
cyst diameter reduction. Secondary objectives are to
determine symptomatic relief and cyst recurrence.
Hypothesis
We hypothesize that administrating pasireotide curtails
fluid re-accumulation following AS and thereby increases
cyst diameter reduction.
Study design and setting
The SCLEROCYST trial is a randomized, double-blind,
placebo-controlled clinical trial. This single-center study
is performed at the Radboud University Medical Center,
Nijmegen, the Netherlands. Trial duration will be 30 weeks,
consisting of a screening period of four weeks and a treat-
ment period of 26 weeks (Figure 1).
Randomization and treatment allocation
A total of 34 patients will be randomized in a 1:1 ra-
tio to receive either pasireotide or placebo. All pa-
tients will be subjected to AS. Randomization will be
performed using block randomization with a block
size of four. Included patients will be assigned a
randomization number, corresponding to a treatment
arm, concealed in a closed envelope. Access to treat-
ment allocation will be restricted to research nurses
who prepare and administer the injections. Both pa-
tients and treatment allocators will be unaware of the
allocated treatment.
Study population
All patients who are diagnosed with a symptomatic, hep-
atic cyst that meet the following eligibility criteria will be
suitable for participation in this study.
Inclusion criteria
The inclusion criteria for this study are as follows:
1. Aged between 18 and 70 years,
2. Indication for treatment with AS, made upon
diagnosis of a symptomatic, simple hepatic cyst
exceeding 5 cm in diameter,
3. The treated hepatic cyst must be solitary or dominant
by nature; a dominant hepatic cyst is the largest cyst
surrounded by multiple smaller cysts in patients with
PLD and
4. Provision of informed consent to participate.
Exclusion criteria
The aspiration sclerotherapy-related exclusion criteria
are as follows:
1. Suspicion of a complicated hepatic cyst (active cyst
hemorrhage, rupture, or infection),
2. Coagulopathy (international normalized ratio (INR)
>2 or platelet count <80 × 109/l) or
3. Severe co-morbidity contraindicating anesthesia
(ASA 4 classification).
The pasireotide treatment-related exclusion criteria
are as follows:
1. Known long QT syndrome and/or corrected QT
interval (QTc) at screening >470 ms;
2. Family history of long QT syndrome or idiopathic
sudden death;
3. Uncontrolled or significant cardiac disease including
a recent myocardial infarction, congestive heart
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failure, unstable angina or sustained and/or clinically
significant cardiac arrhythmias;
4. Risk factors for torsades de pointes: hypokalemia,
hypomagnesemia, hypocalcaemia, clinically
significant bradycardia or high grade atrioventricular
block;
5. Concomitant disease that could prolong QT interval
such as autonomic neuropathy, HIV, cirrhosis,
uncontrolled hypothyroidism or cardiac failure;
6. Use of anti-arrhythmic medicinal products or other
substances known to lead to QT interval
prolongation;
7. Symptomatic cholecystolithiasis;
8. Uncontrolled diabetes, defined as glycated
hemoglobin (HbA1C) level >64 mmol/ml despite
adequate therapy;
9. Moderate to severe hepatic impairment defined by a
Child-Pugh classification of more than six points;
10.History of acute pancreatitis;
11.Hypersensitivity to somatostatin analogues or any
component of pasireotide or
12.Non-malignant medical illnesses that are
uncontrolled or whose control may be jeopardized
by the treatment with the study therapy.
Further exclusion criteria are as follows:
1. Pregnant or nursing women,
2. Use of oral contraception or estrogen
supplementation,
3. Intervention (aspiration with or without
sclerotherapy or surgical intervention) within six
months prior to baseline,
4. Treatment with somatostatin analogues within six
months prior to baseline or
5. Any current or prior medical condition that may
interfere with the conduct of the study or the
evaluation of its results in the opinion of the
investigator.
Trial treatments
Aspiration sclerotherapy
All included patients will undergo AS of a single hepatic
cyst following standard of care. This single session pro-
cedure will be performed by one of our five interven-
tional radiologists, experienced in performing AS.
Patients will be admitted the day of AS and will receive
intravenous antibiotic prophylaxis (cefazolin 1,000 mg
(Eurocept, Ankeveen, the Netherlands) or clindamycin
600 mg (Sandoz, Holzkirchen, Germany) as an alterna-
tive in case of allergies). The procedure will be carried
out with conscious sedation. Briefly, the cyst will be local-
ized by ultrasonography. Following disinfection and local
anaesthesia of the skin, a 5 French pigtail catheter (Cook
Medical, Bloomington, United States of America) attached
to a three-way tap will be inserted in the hepatic cyst to
perform complete fluid evacuation (aspiration). Cyst leak-
age or communication with vessels or bile ducts will be
examined by instillation of contrast medium (Iomeron
300, Bracco Imaging, Konstanz, Germany, up to 20 ml)
into the cyst cavity. Contrast medium will then be aspi-
rated from the cyst followed by an injection of 100% etha-
nol (sclerotherapy). The amount of instilled ethanol
consists of 10% of the aspirated cyst volume (up to a max-
imum of 50 ml). After 10 minutes, ethanol is aspirated
and the drain will be removed.
Pasireotide
Subjects in the active treatment arm will receive two
intragluteal injections of 60 mg pasireotide (SOM230,
Figure 1 Study design of the SCLEROCYST trial. AS, aspiration and sclerotherapy; INJ, injection of pasireotide or placebo; Q, assessment of
GIS-, PLD- and SF-36 questionnaires; US, ultrasonography.
Wijnands et al. Trials  (2015) 16:82 Page 3 of 8
Novartis, Basel, Switzerland) long-acting release (LAR).
The first injection will be administered two weeks prior
to AS, the second injection will be administered two
weeks following AS. Pasireotide LAR, powder for sus-
pension for injection, is a one-month depot microparti-
cle formulation for intramuscular administration. No
dose adjustment is required for race, age, gender, body
weight, mild hepatic impairment or renal impairment.
The most common adverse events are gastrointestinal
by nature and include mild diarrhea, nausea and abdom-
inal pain [18]. These events are more frequent in the
first days after treatment initiation and mitigate within
time. Moreover, transient hyperglycemia, local injection
site skin reactions and headaches are common side ef-
fects of pasireotide [18,19]. Previous studies have indi-
cated that pasireotide may prolong the QT interval [20].
Therefore, patients with a prolonged QTc at screening
(>470 ms) are not eligible to participate in this study.
Known long-term side effects, such as development of
gallstones, are not expected in this study given the lim-
ited number of injections.
Placebo
Patients in the placebo arm will receive two intragluteal
injections of 2 ml sodium chloride solution 0.9% (Fresenius
Kabi, Hesse, Germany). The first injection will be adminis-
tered two weeks prior to AS and the second injection will
be administered two weeks following AS.
Study endpoints
Primary outcome
The primary outcome of the SCLEROCYST trial is the
mean proportional change (%) in cyst diameter of the
treated hepatic cyst four weeks after AS, as measured by
ultrasound.
Secondary outcome
Secondary outcomes are mean proportional change (%)
in cyst diameter two, 12 and 24 weeks after AS. More-
over, proportional change (%) in volume, absolute diam-
eter reduction (cm) and rate of cyst recurrence (>80% of
original diameter) at follow-up visits will be assessed. In
addition, symptoms and health-related quality of life will
be measured at baseline, four, 12 and 24 weeks after AS.
Finally, any complications or adverse events reported
during procedure or follow-up visits will be recorded.
Ultrasound measurements
The blinded primary investigator will perform cyst diam-
eter measurements by ultrasonography. The treated hep-
atic cyst will be visualized in two planes to measure each
maximal orthogonal diameter (craniocaudal, anteropos-
terior and mediolateral) three times. As a secondary
endpoint, cyst volume will be estimated by multiplying
the maximum of each orthogonal diameter by 0.523
[10]. The measurement will be performed using a
3.5 MHz convex transducer (Acuson X150™, Siemens
Healthcare, Erlangen, Germany). A blinded independent
investigator will repeat all measurements. Both investiga-
tors are trained and experienced in measuring hepatic
cyst diameter.
Patient-reported outcome measures
Abdominal symptoms and health-related quality of life
will be assessed at screening and during follow-up visits.
The standardized gastrointestinal symptom question-
naire (GIS) assesses 11 abdominal symptoms using a
seven-point Likert scale ranging from 0 (‘none’) to six
(‘severe’) [21]. The Medical Outcomes Study 36-item
short-form health survey (SF-36) will be completed to
evaluate health-related quality of life [22]. This generic
questionnaire assesses health-related quality of life in
eight different domain scores and two summarizing
(physical and mental) component scores. Additionally, a
disease-specific questionnaire for PLD in development
(PLD-Q, Radboud University Medical Center, Nijmegen)
that assesses frequency and discomfort of 16 PLD-
related symptoms over a timeframe of one month, will
be completed by all subjects in order to validate this in-
strument in patients treated for large symptomatic hep-
atic cysts.
Study procedures
This study consists of seven visits including one screen-
ing visit, three treatment visits and three follow-up
visits.
Screening visit (within four weeks prior to starting the trial)
Potential subjects with an indication for AS will be asked
to participate. Informed consent will be obtained from
all participants. Upon providing informed consent, each
subject will be screened for eligibility during a separate
screening visit performed within 28 days prior to the
start of the trial. During this screening visit the following
assessments will be made:
1. obtain written informed consent;
2. extensive medical history and physical examination;
3. laboratory markers: potassium, calcium, magnesium,
estimated glomerular filtration rate calculated by the
Modification of Diet in Renal Diseases (MDRD)
formula, platelets, INR, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline
phosphatase (ALP), gamma-glutamyl transpeptidase
(GGT), total bilirubin (TB), albumin and fasting
blood sugar (FBS);
4. urine pregnancy test in female patients with
childbearing potential;
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5. electrocardiogram: frequency, QTc and
atrioventricular conduction;
6. ultrasonography: cyst diameter and volume
measurement and
7. questionnaires: GIS-, PLD- and SF-36 questionnaire.
First injection (week 0)
The first injection will be administered 14 days prior to
AS and indicates the start of this trial. Patients in the
treatment arm will receive the first injection of pasireo-
tide LAR 60 mg, while patients in the placebo arm will
receive an injection of the sodium chloride solution. The
injections will be administered by an independent un-
blinded health professional who is not involved in the
design, execution or analysis of the trial.
Aspiration sclerotherapy (week two)
Patients will be admitted the day of AS. Prior to the
intervention, adverse events in the previous two weeks
will be assessed. Moreover, blood will be drawn to evalu-
ate safety laboratory markers (potassium, magnesium,
FBS, ALT, AST, TB and amylase). AS will be performed
following standard procedure in both arms. Aspirated
cyst fluid will be stored in our laboratory for future
analyses.
Second injection (week four)
Two weeks following AS (four weeks following the first
injection) the patient will visit the outpatient clinic to
receive the second injection. Cyst diameter will be
assessed. All adverse events will be documented and
blood will be obtained. If the following laboratory par-
ameter levels are found, the second injection will not be
administered:
1. FBS >9.9 mmol/l;
2. AST or ALT >5 × upper limit of normal (ULN);
3. AST or ALT >3 × ULN with TB >2 × ULN or
4. amylase >10 × ULN.
If the parameters fall within the margin of safety, the
second injection will be administered.
Follow-up visits (week six, 14 and 26)
Three follow-up visits will be planned at six, 14 and
26 weeks following the first injection (four, 12 and
24 weeks following AS). The researcher will document
adverse events and blood will be drawn to assess safety
laboratory markers (FBS, ALT, AST, ALP and GGT).
The diameter of the treated cyst will be captured and
cyst volume will be calculated. The primary endpoint of
this study, mean proportional change (%) in cyst diam-
eter at four weeks after AS, will be obtained during the
first follow-up visit. Furthermore, abdominal symptoms
and health-related quality of life will be measured using
the GIS-, PLD- and SF-36 questionnaires.
Study withdrawal
Subjects can withdraw informed consent and leave the
study at any time. The investigator will withdraw a sub-
ject from the study for any of the following reasons:
pregnancy, consistent failure to adhere to protocol re-
quirements, unacceptable toxicity of study medication,
surgical interventions during the study or any other rea-
son if in the best interest of the patient. All data gener-
ated up to the time of discontinuation from the study
will be analyzed and the reason(s) for discontinuation
will be recorded.
Sample size considerations
Recent data showed that patients treated by AS have a
mean diameter reduction of 29.7 ± 19.76% after four
weeks [23]. By adding pasireotide, we want to establish a
decrease in cyst diameter of 50% after four weeks. A
sample size of 15 patients per arm, leading to a total of
30 patients, is required to be able to obtain a significant
difference between the two groups (power: 80%; α: 0.05).
Taking into account the possibility of 10% protocol vio-
lators and/or dropouts, we aim to include 17 subjects
per arm, giving a total of 34 patients.
Statistical analysis
Intention-to-treat (ITT) analyses will be used for all
clinical outcome variables. The ITT sample includes all
patients who received at least one dose of study medica-
tion. In addition, we will carry out a parallel analysis on
the per-protocol treated population. This sample is de-
fined as all patients who have received both injections,
AS and all ultrasound measurements. The primary out-
come of this study is the proportional (%) change in cyst
diameter of the treated hepatic cyst four weeks after AS,
as measured by ultrasound. The mean diameter of each
orthogonal diameter measured by the blinded primary
investigator will be used for analysis. Subsequently, we
will calculate a mean diameter from the three mean or-
thogonal diameters. Proportional change will be calcu-
lated by dividing the reduction of mean cyst diameter at
four weeks by mean cyst diameter at baseline, multiplied
by 100. Depending on distribution, values will be pre-
sented as mean ± SD or as median ± interquartile range.
Consequently, differences between the treatment and
placebo arm will be calculated using the independent
student’s t-test or the Mann-Whitney U test, respect-
ively. Absolute reduction and volume reduction will be
presented and analyzed similar to data for the primary
endpoint. Cyst recurrence will be compared between
both groups using Fisher’s exact test. The cyst diameter
measurements from the second blinded investigator will
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be used as a control to evaluate intra- and interobserver
variability by performing a Bland-Altman analysis. Symp-
toms of the GIS-questionnaire will be dichotomized (0 to
oneversus two to six) and compared between the treat-
ment and placebo arm using the chi-square test. Health-
related quality of life domain scores and component
scores (SF-36) will be compared between both arms using
the Mann-Whitney U test. Frequency tables will be com-
piled for (serious) adverse events classified according to
the standard World Health Organization - Adverse Reac-
tion Terminology (WHO-ART) Body System Dictionary
and preferred terms. All statistical analyses will be two-
sided, with a critical significance level of 5%.
Ethical considerations
Ethical approval of the study protocol was given by the
Central Committee on Research Involving Human
Subjects and by the local accredited Medical Research
Ethics Committee of the region Arnhem-Nijmegen, the
Netherlands (reference number: 2013/354). This study
is to be conducted in accordance with the International
Conferences of Harmonization Good Clinical Practice
Guidelines, the principles of the Declaration of Helsinki
1964 as modified by the 52nd WMA General Assembly,
Edinburgh, Scotland, October 2000 including two notes of
clarification on paragraph 29 and 30, and the local na-
tional laws governing the conduct of clinical research
studies. An independent data and safety monitoring board
has been formed to monitor patient safety and treatment
efficacy during the trial.
Discussion
The SCLEROCYST trial is designed to evaluate the
additional effect of pasireotide on hepatic cyst diameter
reduction in patients treated by AS. We hypothesize that
complementary pasireotide treatment results in an aug-
mented treatment efficacy. Multiple studies have shown
that AS is an effective and safe method to reduce hepatic
cyst volume [7,23,24]. However, cyst reduction is cur-
tailed by fluid re-accumulation following treatment [10].
Fluid secretion by cyst-lining cholangiocytes is mediated
by intracellular 3′-5′-cyclic adenosine monophosphate
(cAMP). Increased levels of cAMP lead to activation of
cystic fibrosis transmembrane conductance regulator
(CFTR). Opening of these chloride channels results in
chloride efflux, with a subsequent osmotic gradient fa-
cilitating water transport into the cyst cavity [17,25].
Somatostatin analogues inhibit cAMP by activating the
somatostatin receptor (SSTR), and thereby reduce cholan-
giocyte fluid production [12,17,26]. Indeed, previous ran-
domized clinical trials showed that both octreotide and
lanreotide are capable of reducing cystic liver volume [27].
In the context of this study we want to evaluate
whether these inhibitory mechanisms of somatostatin
analogues can halt cyst fluid re-accumulation following
AS. We have chosen to apply the multi-receptor-
targeted, long-acting somatostatin analogue pasireotide
(SOM230) [16]. This cyclohexapeptide has a high bind-
ing affinity to SSTR 1, 2, 3 and 5 which are all expressed
on cholangiocytes [12]. Compared to conventional som-
atostatin analogues, pasireotide has a broader binding
profile and a higher affinity to SSTR 1, 3 and 5. In a
polycystic kidney disease rodent model pasireotide de-
creased intracellular cAMP, cholangiocyte proliferation
and expansion of hepatic cysts more effectively than
octreotide [17]. Pasireotide is approved in the European
Union and United States for the treatment of Cushing’s
disease, and is currently being investigated for treatment
of other diseases such as acromegaly and neuroendo-
crine tumors. Two formulations of pasireotide are avail-
able: an immediate release and a one-month depot
formulation. To ensure adequate pasireotide levels and
optimize patient adherence, we have chosen to administer
the LAR formulation of pasireotide. A previous pharma-
cokinetic study of pasireotide LAR in healthy volunteers
showed that pasireotide levels reached a peak (tmax)
around 20 days following administration [18]. Therefore,
to secure adequate levels subsequent to AS, a first injec-
tion will be administered two weeks prior to AS, followed
by a second injection two weeks following AS.
The strength of this study is its design: a randomized,
double-blind, placebo-controlled trial. This will minimize
confounding of results. Further, this study is powered on a
clinical relevant difference of 50% in the pasireotide arm
compared to the expected 30% cyst diameter reduction in
the control arm. We believe that a statistical significant
finding will have direct implications for future AS treat-
ment. Smaller differences between arms will not be de-
tected in view of power issues. Nevertheless, given the
additional costs and potential side effects of pasireotide,
we believe that a strong improvement over conventional
AS is needed to justify the implementation of this combin-
ation treatment. Finally, with this study we hope to
achieve a better understanding in the pathological mecha-
nisms behind hepatic cyst development and fluid re-
accumulation following AS.
This study has several limitations. First, the effect of
treatment will be measured by ultrasonography. Since
we will perform cyst measurements within short inter-
vals we have selected ultrasonography as the most
appropriate imaging modality to avoid exposure to radi-
ation (from computed tomography scans) and high costs
(from magnetic resonance imaging). However, ultra-
sound measurements are operator-dependent and are
therefore susceptible to bias. To minimize biased results,
we have added several safety measures. All measure-
ments will be performed according to standard operating
procedures and will be executed in triplicate. Moreover,
Wijnands et al. Trials  (2015) 16:82 Page 6 of 8
all measurements will be performed by the same investiga-
tor who is blinded for treatment allocation. In addition, a
second, blinded independent investigator will repeat all
measurements. Second, in this study sclerotherapy will be
performed with 100% ethanol. Multiple sclerosing agents
are in use for AS ranging from ethanol to tetracycline an-
tibiotics, polidocanol, ethanolamine oleate or hypertonic
saline [8,28-32]. This might limit the generalization of our
findings. On the other hand, ethanol is cheap, widely avail-
able and the clinical experience with this agent is large. Fi-
nally, AS will be performed by a number of interventional
radiologists, theoretically introducing performance bias.
Nevertheless, AS is a protocol procedure and large differ-
ences in treatment outcome between interventional radi-
ologists are not to be expected.
To summarize, the SCLEROCYST trial is designed to
evaluate the additional effect of a somatostatin analogue
combined with AS. We aim to reduce fluid re-
accumulation following treatment leading to increased
cyst diameter reduction and symptomatic relief.
Trial status
The trial is currently ongoing. Recruitment and inclusion
of patients started in April 2014.
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